Sign in to view content

3-Year Update for the Phase 3 Voretigene Neparvovecrzyl Study in Biallelic RPE65 Mutation–Associated Inherited Retinal Disease

Stephen R. Russell, MD

Video
Published 2018

Related

Efficacy, Durability, and Safety of Faricimab in DME: 2-Year Results From the Phase 3 YOSEMITE and RHINE Trials
Jennifer I. Lim, MD, FARVO, FASRS
Updates from the Field
2022
Ranibizumab for Radiation Retinopathy (RRR) A Prospective, Multicenter Trial of Monthly Versus PRN Dosing for Radiation Retinopathy-Related Macular Edema
Rajiv Anand, MD, FRCS, FASRS
Annual Meeting Talks
2018
Episode 5: Adding Dexamethasone Implant to Ranibizumab for Persistent DME with Dr. Raj Maturi
Keyvan Koushan, MD, FRCSC
Member Podcasts
2017

Category: Hereditary Retinal Disease & Genetics

See more